Evidence map›Paper›PMID 30032332›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2018

Pimavanserin use in a movement disorders clinic: a single-center experience.

Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Peter LeWitt, Danette Taylor, Shana Krstevska, Neepa Patel

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Abhimanyu MahajanParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.ORCID http://orcid.org/0000-0001-8807-6672
Bisena BulicaParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Ayesha AhmadParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Patricia KaminskiParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Peter LeWittParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Danette TaylorParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Shana KrstevskaParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Neepa PatelParkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA. npatel20@hfhs.org.
Henry Ford Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease psychosis (PDP) is a disabling non-motor symptom of Parkinson's disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT

methodsA retrospective chart review of patients prescribed pimavanserin was performed in August, 2017. Data on demographics, psychotic features, sleep, and adverse effects was collected using a semi-structured telephone interview with patients or caregivers. Hallucination severity (HS) was quantified as mild (< 1 episode/week), moderate (1/week to < 1/day), or severe (daily/continuous).

resultsSeventeen patients consented to participate in the study; 16 were diagnosed with PDP, 1 with Lewy body dementia. Fourteen had co-morbid cognitive impairment/dementia. The mean duration of Parkinsonism was 11.8 ± 8.0 years, with 2.6 ± 1.9 years of psychosis. Eleven of the seventeen patients reported improvement of hallucinations of which 5/8 were initiated on pimavanserin monotherapy, and 6/9 reported improvement of HS with combination of DRB. Six of nine patients prescribed DRB were able to discontinue this medication after introduction of pimavanserin. Four patients discontinued medications (2, no benefit; 1, spontaneous resolution; 1, cost). No major side effects were reported, and two patients noted subjective improvement of sleep.

conclusionIn our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.

Indexed as

AgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedMovement DisordersPiperidinesRetrospective StudiesSerotonin 5-HT2 Receptor AgonistsSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeUreapimavanserinPiperidinesSerotonin 5-HT2 Receptor AgonistsUreaHallucinationsParkinson’s diseaseParkinson’s disease psychosisPimavanserin

Identifiers

PMID30032332
OpenAlexW2801538281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.